About

Iboganon is an independent information resource on ibogaine for people researching ibogaine. We exist to gather evidence, clarify safety considerations, outline legal context, and surface practical questions — all framed for families and individuals seeking reliable information.

Our editorial approach

We collect and summarize primary sources, regulatory notices, clinical registries, and peer-reviewed literature to present context that a family member or researcher can evaluate. When describing risk, procedure, or legal status we aim to cite public registries and official guidance rather than rely on anecdotes.


How content is sourced

Our content is assembled from verifiable records: clinical trial registries, indexed journals, and official safety advisories. For example, organizations like the U.S. National Library of Medicine maintain registries that inform clinical context and are used as source material when relevant National Library of Medicine.

Editorial principles

We publish with an evidence-first, audience-centered approach. Our short principles guide sourcing, language, and transparency.

  • Independence: We do not provide clinical services or treatment; our role is informational and editorial.
  • Plain language: Complex findings are translated into clear summaries for families and non-specialists.
  • Source transparency: Every substantive claim is linked to public registries or peer-reviewed work when possible.
  • No fabricated credentials: We do not invent staff titles, clinical affiliations, or endorsements.

Who this is for

Our audience is people researching ibogaine and those supporting them. If you are evaluating information about treatment options or safety, our content is organized to surface the evidence and the gaps so families can ask informed questions of clinicians and regulators.

For readers wanting to explore services mentioned as context, we link to clinical and service pages where appropriate; for example, some practical resources are described on service provider pages such as the clinic directory we reference in coverage ibogaine treatment clinic listings in Mexico.

We also provide general links to standards and summaries from recognized institutions to support factual claims, for example policies or safety summaries available from established public resources like the U.S. Centers for Disease Control and Prevention CDC and background articles summarizing pharmacology on encyclopedia-level references Wikipedia's ibogaine overview.

Site structure and navigation

Content is divided by practical need: services & logistics, medical risk primer, family decision guides, and aftercare resources. Each section contains summaries, source links, and signposts to more technical material when available. If you want to return to our front page description of themes and navigation, see the site overview on the Iboganon landing pages.

When topics connect — for instance when procedural context intersects with aftercare — we cross-link between related sections such as services and the aftercare guidance so readers can follow a coherent path through the material.

Editorial frequently asked questions

How do you choose sources?
We prioritize primary literature, clinical trial registries, official advisories, and academic syntheses. When summarizing risk we favor data drawn from indexed studies and public safety notices to reduce reliance on unverified anecdotes.
Do you offer referrals or treatment?
No. We do not provide referrals, medical services, or treatment. For information about provider locations or clinics we may link to external service directories; such links are informational only and do not constitute endorsement.
How can readers suggest corrections?
Corrections and source suggestions are accepted through our contact route; details are on the contact page. We review suggested edits and update content when verifiable sources support a change.